Edition:
United Kingdom

Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

1.36USD
14 Dec 2018
Change (% chg)

-- (--)
Prev Close
$1.36
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,386,826
52-wk High
$6.99
52-wk Low
$1.35

Latest Key Developments (Source: Significant Developments)

Geron Corp Reports Q3 Revenue $165,000
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Geron Corp ::REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT COMPANY EVENTS.Q3 LOSS PER SHARE $0.03.Q3 REVENUE $165,000.HAVE CASH TO COMMENCE ENROLLMENT FOR PHASE 3 PORTION OF IMERGE BY MID-YEAR 2019.ENDED Q3 OF 2018 WITH $184.8 MILLION IN CASH AND MARKETABLE SECURITIES.  Full Article

Geron Announces Discontinuation Of Imetelstat Collaboration By Janssen
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Geron Corp ::GERON ANNOUNCES DISCONTINUATION OF IMETELSTAT COLLABORATION BY JANSSEN.GERON CORP - GERON PLANS TO INITIATE PHASE 3 PORTION OF IMERGE.GERON CORP - GERON PLANS TO INITIATE PHASE 3 PORTION OF IMERGE.GERON CORP - REGAINS GLOBAL RIGHTS TO IMETELSTAT PROGRAM.GERON CORP - EFFECTIVE DATE OF TERMINATION IS SEPTEMBER 28, 2018.GERON - TRANSITION OF IMETELSTAT PROGRAM TO GERON IS EXPECTED TO OCCUR OVER APPROXIMATELY 12 MONTHS WITH OPERATIONAL SUPPORT FROM JANSSEN.GERON - JANSSEN IS EXPECTED TO SUPPLY IMETELSTAT TO GERON FOR UP TO 24 MONTHS DURING TRANSITION PERIOD FOR CLINICAL MANUFACTURING.GERON CORP - REVISED ITS FINANCIAL PROJECTIONS AND NOW ANTICIPATES 2018 OPERATING EXPENSES TO BE APPROXIMATELY $37 MILLION.GERON CORP - PLANS TO INITIATE PHASE 3 PORTION OF IMERGE AFTER SPONSORSHIP OF ONGOING IMETELSTAT CLINICAL TRIALS TRANSFERRED FROM JANSSEN TO CO.GERON CORP - ANTICIPATES PATIENT SCREENING AND ENROLLMENT FOR PHASE 3 PORTION OF IMERGE TO BEGIN BY MID-YEAR OF 2019.GERON CORP - HAS ENGAGED A GLOBAL CONTRACT RESEARCH ORGANIZATION (CRO) TO SUPPORT IMETELSTAT CLINICAL DEVELOPMENT.GERON-AS OF AUG 31, HAD ABOUT $183 MILLION IN CASH, MARKETABLE SECURITIES; EXPECTED TO BE SUFFICIENT TO SUPPORT PLANS TO INITIATE PHASE 3 OF IMERGE IN 2019.GERON - EXPECTS FINAL DATA FROM PHASE 2 PORTION OF IMERGE TO BE AVAILABLE IN 2019.  Full Article

Geron Corp Files For Mixed Shelf Offering Of Up To $250 Mln
Thursday, 24 May 2018 

May 24 (Reuters) - Geron Corp ::GERON CORP FILES FOR MIXED SHELF OFFERING OF UP TO $250 MILLION - SEC FILING.  Full Article

Geron Reports Q1 Revenue $318,000
Thursday, 10 May 2018 

May 10 (Reuters) - Geron Corp ::GERON CORPORATION REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.04.Q1 REVENUE $318,000.  Full Article

Geron-Latest Time For Janssen Continuation Decision To Continue Development Of Imetelstat In Any Indication Expected By Q4 2018/Q1 2019
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Geron Corp ::GERON -LATEST TIME FOR JANSSEN CONTINUATION DECISION TO CONTINUE DEVELOPMENT OF IMETELSTAT IN ANY INDICATION EXPECTED BY Q4 2018/Q1 2019 - SEC FILING‍​.  Full Article

Geron says first patient dosed in expanded part 1 of imerge clinical trial in myelodysplastic syndromes
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Geron Corp ::Geron announces first patient dosed in expanded part 1 of imerge clinical trial in myelodysplastic syndromes.  Full Article

Geron Corp Q3 loss per share $0.04
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Geron Corp ::Geron Corporation reports third quarter 2017 financial results.Q3 loss per share $0.04.Q3 revenue $163,000.Q3 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S.Q3 revenue view $264,000 -- Thomson Reuters I/B/E/S.  Full Article

Geron announces fast track designation grant for imetelstat
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Geron Corp :Geron announces fast track designation granted to imetelstat for lower risk myelodysplastic syndromes.Geron Corp - FDA grants fast track designation for potential treatment of adult patients with transfusion-dependent anemia​.Geron- J‍anssen sponsored application for fast track designation using preliminary data from clinical trial being conducted by Janssen in lower risk MDS​.  Full Article

US STOCKS-Apple, Amazon set to boost Wall St higher at the open

* Futures up: Dow 0.16 pct, S&P 0.18 pct, Nasdaq 0.38 pct (Adds comment, prices; updates prices)